(Q48456368)

11 February 2018

title

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer (English)

1 reference

11 February 2018

randomized controlled trial

main subject

phase III clinical trial

0 references

1 reference

1 reference

2

Fred Saad

1 reference

11 February 2018

Michael A. Carducci

1

object named as

Michael A Carducci

1 reference

11 February 2018

author name string

Per-Anders Abrahamsson

3

1 reference

11 February 2018

David P Dearnaley

4

1 reference

11 February 2018

Claude C Schulman

5

1 reference

11 February 2018

Scott A North

6

1 reference

11 February 2018

Darryl J Sleep

7

1 reference

11 February 2018

Jeffrey D Isaacson

8

1 reference

11 February 2018

Joel B Nelson

9

1 reference

11 February 2018

Atrasentan Phase III Study Group Institutions

10

1 reference

11 February 2018

language of work or name

English

0 references

publication date

1 November 2007

1 reference

11 February 2018

published in

Cancer

1 reference

11 February 2018

volume

110

1 reference

11 February 2018

issue

9

1 reference

11 February 2018

page(s)

1959-1966

1 reference

11 February 2018

Endothelin-1 promotes proteolytic activity of ovarian carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Expression of endothelin receptor a associated with prostate cancer progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Osteoblasts in prostate cancer metastasis to bone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Role of endothelin-1 in osteoblastic bone metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

ETA receptor mediates the signaling of endothelin-1 in osteoblast-like cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Endothelin-1 and osteoblastic metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Canine prostate stimulates osteoblast function using the endothelin receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Update of REACH-1 and MERIT-HF clinical trials in heart failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Endothelin-1: a multifunctional molecule in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22996

7 January 2021

Identifiers

DOI

10.1002/CNCR.22996

1 reference

11 February 2018

1 reference

11 February 2018